Stonegate Initiates Coverage on Incannex Healthcare

Stonegate Initiates Coverage on Incannex Healthcare

October 02, 2024 | Last Trade: US$1.64 0.01 0.61

Dallas, Texas--(Newsfile Corp. - October 2, 2024) - Incannex Healthcare Inc. (NASDAQ: IXHL): Stonegate Capital Partners initiates their coverage on Incannex Healthcare Inc. (NASDAQ: IXHL)

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

Advancing proprietary, synthetic first and best-in-class cannabinoid and psychedelic-assisted therapeutics
Conducting FDA phase 2/3 trial, IHL-42X, for the treatment of Obstructive Sleep Apnea (OSA)
IHL-42X pivotal phase 2 top-line data expected first half 2025

About Stonegate

Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking services for public and private companies.

Contacts:

Stonegate Capital Partners
(214) 987-4121
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Last Trade:	US$1.64
Daily Change:	0.01 0.61
Daily Volume:	2,815
Market Cap:	US$28.930M

September 30, 2024 Incannex Healthcare Reports Fiscal Full Year 2024 Financial Results and Business Updates September 10, 2024 Incannex Healthcare Announces Strategic Financing for up to $60 Million with Arena Investors August 05, 2024 Incannex Healthcare: FDA Review of PsiGAD2 IND complete; clinical trial for Psilocybin Assisted Psychotherapy in Patients with Generalised Anxiety Disorder to Proceed July 30, 2024 Incannex Healthcare: Dosing completed in 115 participant bioavailability/bioequivalence clinical trial for proprietary sleep apnea drug candidate IHL-42X May 30, 2024 Incannex Healthcare: Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea LOAD MORE NEWS

Featured Stock

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE